BioRem Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

BioRem heeft een totaal eigen vermogen van CA$10.0M en een totale schuld van CA$2.6M, wat de schuld-eigenvermogensverhouding op 25.8% brengt. De totale activa en totale passiva bedragen respectievelijk CA$24.4M en CA$14.4M. De EBIT BioRem is CA$7.1M waardoor de rentedekking 29.9 is. Het heeft contanten en kortetermijnbeleggingen van CA$7.3M.

Belangrijke informatie

25.8%

Verhouding schuld/eigen vermogen

CA$2.57m

Schuld

Rente dekkingsratio	29.9x
Contant	CA$7.27m
Aandelen	CA$9.96m
Totaal verplichtingen	CA$14.42m
Totaal activa	CA$24.38m

Recente financiële gezondheidsupdates

Recent updates

Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)

Oct 11

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

Apr 19

BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

Apr 12

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Jan 25

Is BioRem (CVE:BRM) Using Too Much Debt?

Aug 26

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

Mar 23

BioRem (CVE:BRM) Could Easily Take On More Debt

Aug 25

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

May 20

Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Jan 26

Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

Nov 23

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$21.9M ) BRM } overtreffen de korte termijn passiva ( CA$11.4M ).

Langlopende schulden: De kortetermijnactiva BRM ( CA$21.9M ) overtreffen de langetermijnschulden ( CA$3.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BRM heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van BRM is de afgelopen 5 jaar gestegen van 0% naar 25.8%.

Schuldendekking: De schuld van BRM wordt goed gedekt door de operationele kasstroom ( 210.8% ).

Rentedekking: De rentebetalingen op de schuld van BRM worden goed gedekt door EBIT ( 29.9 x dekking).

BioRem Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Is BioRem (CVE:BRM) Using Too Much Debt?

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

BioRem (CVE:BRM) Could Easily Take On More Debt

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

Recent updates

Investor sentiment improves as stock rises 27%

Third quarter 2024 earnings released: EPS: CA$0.14 (vs CA$0.032 in 3Q 2023)

Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)

Second quarter 2024 earnings released: EPS: CA$0.021 (vs CA$0.006 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.036 loss in 1Q 2023)

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

BioRem Inc., Annual General Meeting, Jun 04, 2024

BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

Full year 2023 earnings released: EPS: CA$0.14 (vs CA$0.10 in FY 2022)

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Investor sentiment improves as stock rises 39%

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.049 in 3Q 2022)

Insufficient new directors

Is BioRem (CVE:BRM) Using Too Much Debt?

New minor risk - Share price stability

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.011 profit in 2Q 2022)

Insufficient new directors

Investor sentiment improves as stock rises 20%

First quarter 2023 earnings released: CA$0.036 loss per share (vs CA$0.007 loss in 1Q 2022)

Full year 2022 earnings released: EPS: CA$0.10 (vs CA$0.036 in FY 2021)

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

Third quarter 2022 earnings released: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021)

BioRem (CVE:BRM) Could Easily Take On More Debt

Second quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.007 in 2Q 2021)

First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 1Q 2021)

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

BIOREM Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: EPS: CA$0.036 (vs CA$0.054 in FY 2020)

Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Third quarter 2021 earnings: Revenues in line with analyst expectations

BIOREM Inc. (TSXV:BRM) announces an Equity Buyback for 23,434,121 shares, for CAD 12.32 million.

High number of new directors

Second quarter 2021 earnings released: EPS CA$0.007 (vs CA$0.009 in 2Q 2020)

High number of new directors

First quarter 2021 earnings released: EPS CA$0.01 (vs CA$0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.05 (vs CA$0.034 loss in FY 2019)

BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.64

BIOREM Inc. Announces Research Project with City of New York to Control Release of Bioaerosols from Waste Water Treatment Facilities

New 90-day high: CA$0.58

BIOREM Inc. Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC Emissions

Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

New 90-day high - CA$0.39

Earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven